The earnings call highlights significant increases in expenses, particularly in employee and consulting costs, which have substantially widened losses. Despite having sufficient cash reserves to finance operations through 2027, the Q&A session revealed management's vague responses and lack of clarity on key issues, such as mutant data disclosure timelines. This uncertainty, combined with rising costs, suggests a negative sentiment, likely leading to a stock price decline in the range of -2% to -8%.